The natural cyclodextrins (CyDs) and the chemically modified hydrophilic CyDs have been extensively used to improve solubility, stability and bioavailability of various insoluble drugs in water. [1][2][3] Among the chemically modified hydrophilic CyDs, oral preparations and parenteral injections containing high amounts of 2-hydroxypropyl-b-cyclodextrin (HP-b-CyD) have been commercialized in the United States and in some parts of Europe. In addition, the pharmaceutical preparations containing sulfobutyl ether-b-CyD (SBE-bCyD) have been hopefully developing. Branched CyDs have some superior characteristics to the parent CyDs and the amorphous CyDs such as HP-b-CyD and SBE-b-CyD: high purity, excellent solubility in water and organic solvents, and lower surface activity. [4][5][6] Another advantage of branched CyDs is a relatively low local irritancy: the hemolytic activity of branched CyDs is lower than those of the parent CyDs, and the leakage of intestinal constituents induced by gluco-4-7) On account of these beneficial properties, branched CyDs are recently expected for pharmaceutical use. However, there is no paper evaluating the cytotoxicity of branched CyDs on gastrointestinal epithelial cells.Caco-2 cells, a human colon adenocarcinoma cell line, have been shown to be a valuable in vitro model of intestinal mucosa. To date, there are a number of studies regarding the passive and active transport of various drugs and cytotoxicity of drugs and absorption enhancers. However, the interactions of branched CyDs such as maltosyl-a-CyD (G 2 -a-CyD) and G 2 -b-CyD with Caco-2 cell monolayers are still unclear, although there are two reports as to the cytotoxicity of DM-bCyD, HP-b-CyD and SBE-b-CyD toward Caco-2 cell monolayers. 8,9) In the present study, the effects of G 2 -a-CyD and G 2 -bCyD on human intestinal epithelial cells were studied using Caco-2 cells and compared with those of natural CyDs (a-, b-and g-CyD) for the following points: 1) viability of the cells, 2) transepithelial electrical resistance (TEER) in the cell monolayers, 3) the apical-to-basolateral (AP-to-BL) or basolateral-to-apical (BL-to-AP) transport of mannitol and rhodamine 123, which are paracellular and transcellular transport markers, respectively, across the monolayers, and 4) the release of biological membrane components such as proteins and phospholipids from the cells into the apical side. To elucidate the difference in the interaction with phospholipids between G 2 -a-CyD or a-CyD, the changes in surface tension of L-a -dipalmitoylphosphatidylcholine (DPPC) monolayers formed onto water by adding G 2 -a-CyD or a-CyD were evaluated.
MATERIALS AND METHODSMaterials a-, b-and g-CyDs were donated by Nihon Shokuhin Kako (Tokyo, Japan). G 2 -a-CyD and G 2 -b-CyD were obtained from Bio Research Corporation of Yokohama (Yokohama, Japan). Tween 20 was purchased from Nacalai Tesque (Kyoto, Japan). Fetal calf serum (FCS) was purchased from Nichirei (Tokyo, Japan). Dulbecco's modified Eagle's medium (DMEM) was obtained from Nissui Pharmaceutical...